Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
Novartis has purchased a subsidiary of IFM Therapeutics LLC focused on developing ani-inflammatory medicines targeting the NLRP3 inflammasome, which will add one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system.
In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of…
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
— Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone — —…
BURTON-UPON-TRENT, England–(BUSINESS WIRE)–Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that Foscavir (foscarnet sodium) has…